SCHEMBL25417355

SCHEMBL25417355

Cc1cc2cc(Br)cc(C)n2n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
TSHR P16473 4/20 0.36
HCRTR1 O43613 1/20 0.34
CASP3 P42574 1/20 0.34
SENP8 Q96LD8 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34
LMNA P02545 1/20 0.32
PIK3CG P48736 1/20 0.32
RECQL P46063 1/20 0.32
CYP1A2 P05177 2/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
HTT P42858 1/20 0.32
KDM4E B2RXH2 2/20 0.31
ALDH1A1 P00352 2/20 0.31
GLA P06280 1/20 0.31
PDE4B Q07343 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21584536 0.77 PDE4B (0.32) NPC1RAB9APDE4B
SCHEMBL21584712 0.74 NPC1 (0.36) NPC1RAB9AHCRTR1CASP3SENP8
SCHEMBL24529390 0.69 NPC1 (0.33) NPC1RAB9AHCRTR1CASP3SENP8
SCHEMBL7947758 0.68 ENPP3 (0.39) NPC1RAB9ALMNACYP1A2KDM4E
SCHEMBL18632452 0.65 AHR (0.39) NPC1RAB9ATSHRHCRTR1CASP3
SCHEMBL4035386 0.65 AHR (0.35) NPC1RAB9ATSHRHCRTR1CASP3
SCHEMBL4099999 0.64 PIK3CG (0.41) NPC1RAB9ATSHRPIK3CGRECQL
SCHEMBL26857578 0.63 PIK3CG (0.49) NPC1RAB9AHCRTR1CASP3SENP8
SCHEMBL17629354 0.62 TSHR (0.53) TSHRLMNARECQLCYP1A2HTT
SCHEMBL20602282 0.61 AHR (0.40) NPC1RAB9ATSHRLMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026753-A1 FUSED TRIAZINONE DERIVATIVES AND METHODS OF USING THE SAME RGENTA THERAPEUTICS, INC. 2025-01-23 US disclosed
WO-2024238793-A1 FUSED TRIAZINONES FOR USE IN THE TREATMENT OF CANCER RGENTA THERAPEUTICS, INC. (US) 2024-11-21 WO disclosed
CN-118871445-A Fused triazinone derivatives and methods of use thereof 亚根达医疗公司 2024-10-29 CN disclosed
WO-2023086959-A1 FUSED TRIAZINONE DERIVATIVES AND METHODS OF USING THE SAME RGENTA THERAPEUTICS, INC. (US) 2023-05-19 WO disclosed
WO-2023086959-A1 FUSED TRIAZINONE DERIVATIVES AND METHODS OF USING THE SAME RGENTA THERAPEUTICS, INC. (US) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026753-A1 FUSED TRIAZINONE DERIVATIVES AND METHODS OF USING THE SAME SF3B5, RBM17, SF3A2 NPC1 992/4885RAB9A 3009/4885TSHR 2427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.